Creso Pharma Ltd uses ground-breaking technology to produce three new CBD tea
The products are based on second-generation newly developed technology optimising CBD content and taste and provide the company with an opportunity to expand its target consumer base into the mainstream convenience food and beverage market.
() (FRA:1X8) has utilised new technology to produce proprietary CBD-based tea products that have been launched in Switzerland with other European markets, including Germany, earmarked for near-term expansion.
The three new products have been launched under the cannaQIX® brand and include cannaQIX® tea, cannaQIX® NITE tea and cannaQIX® Immunity tea.
The new products have been developed based on a new second-generation innovative technology that optimises the CBD content in compliance with regulations and allows for a better taste.
The three new products are:
- cannaQIX® tea designed to help the management of stress supporting a better quality of life;
- cannaQIX® NITE tea developed to be consumed at night-time to support a better sleep; and
- cannaQIX® Immunity tea, which provides the supplements and taste to optimise well-being.
Key component in future production
Creso commercial & development director Gian Trepp said: “We are proud to have completed the finalisation of this ground-breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma.
“The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX® lozenges.
“We look forward to providing further updates on future product additions and our European expansion initiatives.”
Ground-breaking technology
The development of the new products is a ground-breaking technological achievement for Creso Pharma and provides the company with a competitive advantage.
The company will now progress the use of the new technology in the manufacturing of its cannaQIX® lozenge flagship products.
Leveraging distribution network
After completing all the necessary legal and regulatory due diligence, the new tea products can be legally marketed and sold throughout Switzerland, leveraging Creso’s established distribution network comprising more than 2,100 points of sales across Switzerland where Creso’s cannaQIX® products are already sold.
These include pharmacies, pharmacy networks, drugstores, health nutrition shops and large retail groups including leading department store chain Manor.
Creso also supplies all major wholesalers in the country including Galexis, Amedis and Voigt.
Product launch in Germany
The company will also look to launch its new hemp tea products in Germany, following a recent decision by the German Federal Court of Justice to annul previous charges against hemp tea sellers which had temporarily delayed the scheduled Q3 2020 rollout of the company’s products.
This favourable decision puts Creso in a position to actively market and sell its hemp tea products in that jurisdiction without any further regulatory approvals or hurdles to overcome.
European expansion
Upon successful rollout of its new products in Switzerland and Germany, Creso will explore the opportunity to expand the distribution of its hemp tea products into other European companies.
Before launching in other countries, the company will undertake the necessary due diligence to confirm the legality of the sale of its products in each new jurisdiction as required.
Creso expects that its new products will be well received by consumers in future.
Read More: Creso Pharma Ltd uses ground-breaking technology to produce three new CBD tea